Literature DB >> 32920242

Comparing the clinical impact of pancreatic cyst surveillance programs: A trial of the ECOG-ACRIN cancer research group (EA2185).

David S Weinberg1, Constantine Gatsonis2, Herbert J Zeh3, Ruth C Carlos4, Peter J O'Dwyer5.   

Abstract

BACKGROUND: The optimal surveillance strategy for pancreatic cysts, which occur in up to 20% of the adult population, is ill defined. The risk of malignant degeneration of these cysts is low, however the morbidity and mortality associated with pancreatic cancer are high. Two clinical surveillance guidelines are in regular use. Both the Fukuoka and American Gastroenterological Association (AGA) guidelines rely on radiographic and endoscopic imaging. They differ primarily in their recommended frequencies of interval surveillance imaging. While evidence driven clinical guidelines should promote higher quality care, competing guidelines on the same topic may provide discordant recommendations and potential reduction in the quality and/or value of care.
OBJECTIVES: The primary objective is to compare the clinical effectiveness of the two surveillance guidelines to identify patients most likely to benefit from pancreatic resection. Secondary objectives include comparison of resource utilization, patient reported outcomes, incidental findings are other clinical outcomes.
METHODS: 4606 asymptomatic patients with newly identified pancreatic cysts ≥1 cm in diameter will be randomized 1:1 to high intensity (Fukuoka) or low intensity (AGA) surveillance. All participants will be followed prospectively for 5 years.
CONCLUSION: Differing guidelines confuse providers, patients and policymakers. This large, prospective, randomized trial will compare the clinical effectiveness and resource allocation requirements of two guidelines addressing a common clinical entity. CLINICALTRIALS. GOV IDENTIFIER: NCT04239573.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical effectiveness; Cost-effectiveness; Pancreatic cancer; Pancreatic cyst; Randomized controlled trial

Year:  2020        PMID: 32920242      PMCID: PMC7686040          DOI: 10.1016/j.cct.2020.106144

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  19 in total

Review 1.  Overdiagnosis in cancer.

Authors:  H Gilbert Welch; William C Black
Journal:  J Natl Cancer Inst       Date:  2010-04-22       Impact factor: 13.506

2.  Accuracy of Fukuoka and American Gastroenterological Association Guidelines for Predicting Advanced Neoplasia in Pancreatic Cyst Neoplasm: A Meta-Analysis.

Authors:  Jiayuan Wu; Yufeng Wang; Zitao Li; Huilai Miao
Journal:  Ann Surg Oncol       Date:  2019-10-15       Impact factor: 5.344

3.  American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts.

Authors:  Santhi Swaroop Vege; Barry Ziring; Rajeev Jain; Paul Moayyedi
Journal:  Gastroenterology       Date:  2015-04       Impact factor: 22.682

4.  Incidental findings in the pancreas (and elsewhere): putting our patients (and ourselves) in a difficult situation.

Authors:  Russell P Harris
Journal:  Ann Intern Med       Date:  2015-06-02       Impact factor: 25.391

Review 5.  American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts.

Authors:  James M Scheiman; Joo Ha Hwang; Paul Moayyedi
Journal:  Gastroenterology       Date:  2015-04       Impact factor: 22.682

6.  Management of pancreatic cysts: the evidence is not here yet.

Authors:  Carlos Fernández-Del Castillo; Masao Tanaka
Journal:  Gastroenterology       Date:  2015-02-25       Impact factor: 22.682

Review 7.  Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas.

Authors:  Masao Tanaka; Carlos Fernández-Del Castillo; Terumi Kamisawa; Jin Young Jang; Philippe Levy; Takao Ohtsuka; Roberto Salvia; Yasuhiro Shimizu; Minoru Tada; Christopher L Wolfgang
Journal:  Pancreatology       Date:  2017-07-13       Impact factor: 3.996

8.  Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer.

Authors:  Richard M Hoffman; Tania Lobo; Stephen K Van Den Eeden; Kimberly M Davis; George Luta; Amethyst D Leimpeter; David Aaronson; David F Penson; Kathryn Taylor
Journal:  Med Decis Making       Date:  2019-10-21       Impact factor: 2.583

9.  Pancreatic cyst prevalence and the risk of mucin-producing adenocarcinoma in US adults.

Authors:  Timothy B Gardner; Lisa M Glass; Kerrington D Smith; Gregory H Ripple; Richard J Barth; David A Klibansky; Thomas A Colacchio; Michael J Tsapakos; Arief A Suriawinata; Gregory J Tsongalis; J Marc Pipas; Stuart R Gordon
Journal:  Am J Gastroenterol       Date:  2013-10       Impact factor: 10.864

10.  Monitoring processing style: to see or not to see.

Authors:  Suzanne M Miller
Journal:  Eur J Pain       Date:  2015-04       Impact factor: 3.651

View more
  1 in total

Review 1.  Pancreatic cystic neoplasms: a review of current recommendations for surveillance and management.

Authors:  Justin G Yoon; Daniel Smith; Vijayanadh Ojili; Raj Mohan Paspulati; Nikhil H Ramaiya; Sree Harsha Tirumani
Journal:  Abdom Radiol (NY)       Date:  2021-03-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.